<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02534688</url>
  </required_header>
  <id_info>
    <org_study_id>Kingchulalongkorn</org_study_id>
    <nct_id>NCT02534688</nct_id>
  </id_info>
  <brief_title>Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients</brief_title>
  <official_title>Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Chulalongkorn Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Chulalongkorn Memorial Hospital</source>
  <brief_summary>
    <textblock>
      randomized controlled trial

      Eligiblility criteria Provisional diagnosis Clinical presentation Progressive dysmenorrhea
      Chronic pelvic pain Deep dyspareunia Evidences of endometriosis Endometriotic nodule
      Cul-de-sac nodularity Endometrioma detected by ultrasonography size &lt; 4 cm

      Inclusion criteria Female age 18-45 yr Moderate to severe pelvic pain categorized by VAS &gt;50
      Previous sexual intercourse

      Exclusion criteria Co-existing other genital tract disease associated pain Previous hormonal
      use within 3 months History of DMPA treatment failure WHO eligibility criteria 2009 for DMPA
      and LNG-IUS Category 3,4 Fertility desire in upcoming 1 year

      Primary objective To compare efficacy of pain control in endometriosis associated pelvic pain
      between LNG-IUS and DMPA

      Secondary objective To compare side effect, continuation rate, satisfaction and quality of
      life between LNG-IUS and DMPA in treatment of endometriosis associated pelvic pain

      Primary outcome Severity of pelvic pain Measured by VAS score 0 mean no pain 100 mean most
      pain

      Secondary outcomes Vaginal bleeding pattern Side effects of systemic progestogen Lipid
      profiles Weight gain Quality of life Measured by quesionaire SF36 Satisfaction Measrured by
      linket scale 0-4 0 mean very dissatisfied 1 dissatisfied 2 not satisfied and dissatiffied 3
      satisfied 4 very satisfied Continuation rate Endometrioma size reduction
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of pelvic pain : measured by visual analog scale</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by Quesionaire SF 36 Thai version</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile : total cholesterol, triglyceride, LDL, HDL</measure>
    <time_frame>6months</time_frame>
    <description>Measured by blood collection in mg/dl</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>LNG-IUS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intervention LNG IUS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMPA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three intervention DmPA 12 wk apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LNG-IUS</intervention_name>
    <arm_group_label>LNG-IUS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMPA</intervention_name>
    <arm_group_label>DMPA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female age 18-45 yr

          -  Moderate to severe pelvic pain categorized by VAS &gt;50

          -  Previous sexual intercourse

        Exclusion Criteria:

          -  Co-existing other genital tract disease associated pain

          -  Previous hormonal use within 3 months

          -  History of DMPA treatment failure

          -  WHO eligibility criteria 2009 for DMPA and LNG-IUS Category 3,4

          -  Fertility desire in upcoming 1 year
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>King Chulalongkorn Memmorial hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2015</study_first_submitted>
  <study_first_submitted_qc>August 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2015</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Chulalongkorn Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Kamolrat Daoudom</investigator_full_name>
    <investigator_title>Effectiveness of levonorgestrel-intrauterine system (LNG-IUS) versus depot medroxyprogesterone acetate (DMPA) in treatment of pelvic pain in clinically diagnosed endometriotic patients</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

